Objective: The aim of this study was to investigate the efficacy and prognostic factors of salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer at a single center in Japan. Methods: A retrospective review of the medical records of 51 patients who underwent salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy was carried out. Salvage radiotherapy was undergone for the single indication of at least two consecutive prostate-specific antigen elevations .0.1 ng/ml. Salvage radiotherapy was delivered to the prostatic bed at a total dose of 60 or 64 Gy. Late toxicity was scored according to the Common Terminology Criteria for Adverse Events 3.0. Results: A total dose of 60 and 64 Gy were administered to 26 and 25 patients, respectively. The median prostate-specific antigen level at the initiation of radiotherapy was 0.29 ng/ml (range, 0.11 -1.10 ng/ml). With a median follow-up of 57.3 months (range, 9.9 -134.0 months), the prostate-specific antigen relapse-free rate at 5 years was 50.7%. Multivariate analysis using Cox's proportional hazards regression model revealed that the Gleason score at radical prostatectomy 8 significantly predicted prostate-specific antigen relapse after salvage radiotherapy (hazard ratio 4.531; 95% confidence interval 1.413-14.535; P ¼ 0.011). The prostate-specific antigen relapse-free rate at 5 years in the Gleason score at radical prostatectomy 7 and at radical prostatectomy 8 was 62.7 and 15.4%, respectively. Conclusions: Salvage radiotherapy was effective for prostate-specific antigen relapse after radical prostatectomy with tolerable toxicities in Japanese patients. A high Gleason score seemed to be a poor prognostic factor.
INTRODUCTION
Radical prostatectomy (RP) is an established treatment modality for localized prostate cancer. However, prostatespecific antigen (PSA) relapse occurs in 15 -30% of patients within 5 years after RP (1, 2) . Many retrospective studies have shown that salvage radiotherapy (RT) for PSA relapse is effective for PSA control. For patients with local recurrence after RP, salvage RT is the only potentially curative treatment option. However, it is difficult to determine whether PSA relapse reflects local recurrence or distant metastasis. The prognostic factors for efficacy of salvage RT serve as a guide for the identification of patients with presumed local recurrence. Recent retrospective studies have shown several prognostic factors associated with PSA response to salvage RT (3 -11) . These factors included the PSA level before salvage RT, Gleason score, seminal vesicle invasion, surgical margin status, PSA doubling time (PSADT) and so on.
Although most of studies of salvage RT after RP were reported from Western countries, there were only several studies reported from Japan regarding the outcomes of salvage RT with relatively short follow-up time (12 -15) . Therefore, further investigations on the efficacy of salvage RT for Japanese patients are required. In this study, we investigated the outcomes and prognostic factors of salvage RT for Japanese patients at a single center.
PATIENTS AND METHODS
At the Osaka Medical Center for Cancer and Cardiovascular Disease (OMCC), 691 patients underwent RP and obturator lymph node dissection for clinically localized prostate cancer between January 1995 and December 2008. Of 691 patients, 50 who underwent adjuvant RT or adjuvant hormonal therapy were excluded. Of the remaining 641 patients, 121 (18.9%) developed PSA relapse which was defined as a PSA level of 0.1 ng/ml followed by a second PSA level higher than the first. Of 121 patients with PSA relapse after RP, 57, 18 and 46 underwent salvage RT, salvage hormonal therapy and surveillance at the last contact, respectively. The selection of treatment modalities for PSA relapse after RP was dependent on the patient and the treating urologist. Of 57 patients undergoing salvage RT, 6 who received hormonal therapy during and after salvage RT were excluded. Finally, 51 patients were analyzed in this study.
We reviewed the medical records of the 51 patients undergoing salvage RT for PSA relapse after RP at the OMCC. Salvage RT was undergone for the single indication of at least two consecutive PSA elevations .0.1 ng/ml separated by at least 4 weeks. No patient had pathologically positive lymph nodes. All patients had no evidence of distant metastasis at the time of salvage RT. An anastomosis biopsy was not performed in any patient. Before the start of salvage RT, written informed consent was obtained from all patients who were informed of both the benefits and complications of salvage RT.
Tumors were classified according to the 2002 TNM staging system (16) . The serum PSA level was routinely measured using IMx (Dainabot, Tokyo, Japan; lower detection limit 0.02 ng/ml) until September 2003 and ECLusys PSA (Roche Diagnostics, Basel, Switzerland; lower detection limit 0.003 ng/ml) from October 2003. PSADT calculations were made from all detectable PSA levels from the postoperative PSA nadir during the 12 months before salvage RT. PSADT was estimated for each patient as the reciprocal of the slope from the regression of log-2 PSA on time. Neoadjuvant androgen deprivation therapy (ADT) before RP used to be administered in most patients at our institution in the era when it was unclear whether neaodjuvant ADT improved outcomes of RP. Although it is not recommended that the Gleason sum be scored after neoadjuvant hormonal therapy (17), we scored it in order to have an additional reference for the present evaluations.
Salvage RT was delivered with a four-field box technique using two-dimensional X-ray simulator planning until June 2003, and three-dimensional conformal technique using three-dimensional computed tomography-based planning from July 2003. Salvage RT was delivered using 20 After salvage RT, the serum PSA level was measured every 3 months. PSA relapse after salvage RT was defined as a PSA level of 0.1 ng/ml followed by a second PSA level higher than the first. If the PSA level did not respond but rather continued to increase even after RT, the date of PSA relapse was defined as the start of RT (defined as PSA relapse at 0 month). Late toxicity related to RT was scored according to the Common Terminology Criteria for Adverse Events version 3.0.
PSA relapse-free rates were calculated from the start of salvage RT using the Kaplan -Meier method. The differences between the relapse-free rates in relationship to individual factors were compared using the log-rank test. To identify significant predictors of PSA relapse after salvage RT, multivariate analysis using a Cox's proportional hazards regression analysis was conducted. Probability values of ,0.05 were considered to be significant. All analyses were performed using SPSS v11.0 (SPSS Inc., Chicago, IL, USA). Table 1 summarizes the clinical and pathological characteristics of the 51 patients undergoing salvage RT. Neoadjuvant ADT before RP was administered in 24 (47.1%) patients for a median period of 6.6 months (range, 3.0 -18.9 months). Thirty-two patients had a post-operative nadir PSA after RP ,0.02 ng/ml, whereas 8 had a post-operative nadir PSA after RP .0.1 ng/ml. The median PSA level at the initiation of RT was 0.29 ng/ml (range, 0.11 -1.10 ng/ml). The median age at the initiation of RT was 66 years (range, 56 -75 years). The median time to salvage RT after RP was 13.5 months (range, 4.7 -68.2 months). Salvage RT was delivered with a four-field box technique and three-dimensional conformal technique in 19 and 32 patients, respectively. A total dose of 60 and 64 Gy were administered to 26 and 25 patients, respectively.
RESULTS

1032
Salvage radiotherapy after prostatectomy
With a median follow-up of 57.3 months (range, 9.9 -134.0 months) after salvage RT, 26 patients developed PSA relapse. Nine of these 26 patients had no response to salvage RT and continued to show an increasing PSA level after RT. Five of eight patients with post-operative nadir PSA .0.1 ng/ml developed PSA relapse after salvage RT. Although the clinical decision to initiate hormonal therapy for disease progression after salvage RT was dependent on the patient and the treating urologist, 17 patients started hormonal therapy at a median PSA level of 1.25 ng/ml (range, 0.17 -7.22 ng/ml). Three of these 17 patients suffered from castration refractory prostate cancer at the last contact. No patient died of prostate cancer in this cohort. One patient died of sigmoid colon cancer with castration refractory prostate cancer.
The estimated percentage of patients who were PSA relapse free at 5 years was 50.7% (Fig. 1) . The results from univariate and multivariate analysis are summarized in Table 2 . Multivariate analysis revealed that the Gleason score at RP 8 significantly predicted PSA relapse after salvage RT (hazard ratio 4.531; 95% confidence interval 1.413 -14.535; P ¼ 0.011). Figure 2 shows PSA relapse-free rates using the Kaplan -Meier method according to the Gleason score at RP. The PSA relapse-free rate at 5 years in the Gleason score at RP 7 and 8 was 62.7 and 15.4%, respectively (P , 0.0001, log-rank test).
To investigate the influence of neoadjuvant ADT before RP, 27 patients without neoadjuvant ADT were separately analyzed as a secondary aim. The PSA relapse-free rate at 5 years in these 27 patients was 46.6%. Univariate analysis demonstrated that the Gleason score at RP 8 was an only significant predictor of PSA relapse after salvage RT (P ¼ 0.014, log-rank test). Although the association was not statistically significant, the PSA level before RT of ,0.2 ng/ml tended to improve the PSA relapse-free rate (P ¼ 0.060, log-rank test).
Two (3.9%) and 4 (7.8%) patients developed Grade 1 and 2 hemorrhagic proctitis as a late toxicity, respectively. Three (5.9%) and three (5.9%) patients developed Grade 1 and 3 hemorrhagic cystitis as a late toxicity, respectively. All three patients with Grade 3 hemorrhagic cystitis underwent transurethral coagulation and two received blood transfusion.
DISCUSSION
Management options for PSA relapse after RP are surveillance, hormonal therapy and salvage RT. Many retrospective studies have shown that salvage RT is effective for PSA control, with the 5-year PSA relapse-free rates being between 10.0 and 66.0% (3 -11) . In the present study, the 5-year PSA relapse-free rate was 50.7%, which is comparable to these former studies. However, due to the small number of patients in most of these studies, the retrospective nature of the study designs and the resulting low statistical power, there is a lack of agreement among oncologists regarding the optimal management of patients with PSA relapse after RP. Salvage RT is the only potentially curative treatment option for presumed local recurrence. However, it is difficult to confirm local recurrence at low PSA levels. Thus, prognostic factors for efficacy of salvage RT serve as a guide for the identification of patients with presumed local recurrence. Various prognostic factors for salvage RT have been reported. The PSA level before salvage RT is the most widely accepted predictor of response to RT (3,5 -7,10,18) . However, other factors have also been reported, such as the high Gleason score (3, 7, 15, 18) , seminal vesicle invasion (3 -6,9), surgical margin status (7, 18) and PSADT (5, 10, 15, 18) . The largest multi-institutional, retrospective study was performed by Stephenson et al. (18) in 1540 patients and showed that the statistically significant variables in multivariate analysis were the PSA level before salvage RT, prostatectomy Gleason score, PSADT, surgical margin status, ADT administered before or during salvage RT and lymph node metastasis. In the present analysis, the significant prognostic factor was the Gleason score at RP 8 (P ¼ 0.011), which was comparable to the former studies. While, PSA-related factors, such as the PSA level before RT and PSADT, were not to a statistically significant degree, which was not matched with the former studies. It might be caused by those 24 of the 52 patients (47.1%) in the present cohort who received neoadjuvant ADT before RP, which was a higher rate than other studies. Indeed, in the separate analysis of patients without neoadjuvant ADT, the PSA level before RT tended to improve the PSA relapse-free rate after Figure 1 . Prostate-specific antigen (PSA) relapse-free survival rate after salvage radiotherapy for all patients. 1034 Salvage radiotherapy after prostatectomy salvage RT. It was shown that the serum testosterone level of patients receiving 6 months of gonadotropin-releasing hormone agonists did not return to normal for a median of 16.6 weeks (19) . Therefore, the changes of the PSA level after prostatectomy with neoadjuvant ADT may be different from the changes after prostatectomy without neoadjuvant ADT. Rabbani et al. (20) reported that patients receiving neoadjuvant ADT tended to have a shorter PSADT at PSA relapse compared with those treated only with RP. When a patient with neoadjuvant ADT develops PSA relapse after RP, it is still unclear whether PSA-related factors serve as a prognostic factor for salvage RT.
On toxicities of post-operative RT, large multi-institutional database including 959 men who received salvage (81%) and adjuvant (19%) RT after RP showed that at 5 years, 10% of the patients had Grade 2 late GU toxicity and 1% had Grade 3 late GU toxicity, whereas 4% of the patients had Grade 2 late GI toxicity and 0.4% had Grade 3 late GI toxicity (21) . Both in this large report and the present study, late toxicities were infrequent. However, it is important to consider the risk of such toxicities, since hemorrhagic proctitis and cystitis induced by radiation can be life-threatening conditions requiring blood transfusion, endoscopic surgery or more aggressive treatment.
Since most of the studies of salvage RT after RP were reported from Western countries, there were only several studies reported from Japan regarding the outcomes of salvage RT with relatively short follow-up time (12 -15) . In these studies, the PSA relapse-free rate at 3 years was 55 -74% (Table 3 ). The PSA level before RT, PSADT, Gleason score at RP and RT dose were reported as a significant prognostic factor on univariate or multivariate analysis. The present study showed the results of multivariate analysis with relatively longer follow-up time, even though the small number of patients and the retrospective nature were limitations. The outcomes of salvage RT after RP in Japanese patients showed by these studies including ours were in line with the former studies from Western countries.
The present study was performed in a retrospective fashion and thus does have limitations. One limitation was a selection bias. At our institution, the selection of the postoperative management was dependent on the patient and the treating urologist, which lead to a selection bias. Patients with poor pathological outcomes such as seminal vesicle invasion or with higher post-operative nadir PSA might tend to undergo hormonal therapy rather than salvage RT for relapse. Another limitation was the definition of PSA relapse. PSA relapse after RP is usually defined as 0.2 ng/ml in recent years. However, the most appropriate definition of PSA relapse after RP is still uncertain. Only half of the patients with a PSA of 0.2 ng/ml will progress further after RP (22) . It was also reported that study results did not differ importantly by the definition of PSA relapse (22, 23) . Thus, although the present definition of PSA relapse as 0.1 ng/ml may not be standard, we feel that the present definition can be acceptable. Gleason grading in specimens after neoadjuvant ADT was also a limitation. It is not recommended that the Gleason sum is scored after neoadjuvant hormonal therapy (17) . However, the Gleason score after neoadjuvant ADT was reported to remain a significant prognostic factor after RP, despite the morphologic alterations induced by ADT (24) . Thus, we scored Gleason sum in order to have an additional reference because of its importance.
In conclusion, salvage RT was effective for PSA relapse after RP with tolerable toxicities in Japanese patients. A high Gleason score at RP seemed to be a poor prognostic factor for PSA relapse after salvage RT. Further investigations are required to properly evaluate the efficacy of salvage RT after RP for prostate cancer.
